Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK） is a phase 2, randomised interventional study registered as NCT07005570 by Dechang Diao, with a registry enrolment figure of 86 participants, started 2025-05-01 and due to reach its primary completion in 2027-07-01. Interventions recorded: Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab; Short-course radiotherapy followed by sequential chemotherapy. Conditions listed: pMMR/MSS Locally Advanced Rectal Cancer. Primary outcome: Complete Response (CR) Rate; Adverse events. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.